Chronic Kidney Disease Prognosis Consortium (CKD-PC)

项目总结/摘要 该提案详细介绍了慢性肾脏病预后联盟第三周期（2023 - 2028）的工作 （CKD-PC）。CKD是一个全球性的公共卫生问题，影响着超过10%的世界人口，并且是导致糖尿病的主要原因。 死亡CKD-PC-由约300名研究者组成的全球组，代表> 100个队列， 来自40多个国家的个人-在促进分阶段治疗方面取得重大进展方面发挥了重要作用。 CKD，确定临床试验的替代终点，以及建立一系列风险工具， 临床护理使用（ckdpc.org）。CKD-PC采用高效、流畅的联盟结构、集中式分析， 和创新的荟萃分析方法，以最高水平推进CKD预后的流行病学研究 严格程度、生产力和临床影响。在这一阶段，我们的目标是为肾病指南提供信息， CKD患病率和进展的证据;阐明CKD在心力衰竭风险中的作用， 心律失常，感染，癌症，虚弱和痴呆;并评估肾脏和CKD相关的性能 不同临床环境中的风险工具。当前的挑战包括：量化2021年CKD的影响- EPI方程在世界范围内;确定何时以及多久胱抑素C应测试;并确定 需要对肾脏和CKD相关结局的风险计算器进行局部调整的情况。 我们将继续努力增加区域代表性，提高普遍性，并将 额外的临床试验，以便将观察到的风险映射到真实世界数据， 治疗的门槛。我们保持灵活和高效地应对高优先级的主题， 指南组织和监管机构，如美国食品和药物管理局，以及 与包括全球疾病负担在内的其他联盟合作。我们的首要目标是改善 CKD患者或有CKD风险的患者的健康。

PROJECT SUMMARY/ABSTRACT This proposal details work for the third cycle (2023-2028) of the Chronic Kidney Disease Prognosis Consortium (CKD-PC). A global public health problem, CKD affects >10% of the world population and is a leading cause of death. The CKD-PC – a global group of ~300 investigators representing >100 cohorts with >30 million individuals from >40 countries – has played an important role in facilitating major advances in the staging of CKD, the identification of surrogate endpoint for clinical trials, and the establishment of a range of risk tools for use in clinical care (ckdpc.org). The CKD-PC uses an efficient, fluid consortium structure, centralized analytics, and innovative meta-analysis methods to advance epidemiologic research in CKD prognosis at the highest level of rigor, productivity, and clinical impact. In this phase, we aim to inform guidelines in kidney disease with evidence on CKD prevalence and progression; elucidate the role of CKD in the risk of heart failure, arrhythmias, infections, cancer, frailty, and dementia; and evaluate the performance of kidney and CKD-related risk tools in different clinical settings. Current challenges include: quantifying the implications of the 2021 CKD- EPI equations world-wide; determining when and how often cystatin C should be tested; and identifying situations in which local adaptations of risk calculators for kidney and CKD-related outcomes are warranted. We will work to continue to increase regional representation, enhancing generalizability, and to incorporate additional clinical trials in order to map observed risks to real-world data to inform guideline-recommended thresholds for treatment. We remain flexible and efficient in responding to high priority topics set forth by guideline organizations and regulatory bodies such as the US Food and Drug Administration, and for collaboration with other consortia, including the Global Burden of Disease. Our overarching aim is to improve the health of patients with or at risk for CKD.